Summary
AbbVie Inc. (ABBV) filed an 8-K on July 31, 2020, reporting its financial results for the second quarter ended June 30, 2020. The core of this filing is the furnishing of a press release (Exhibit 99.1) detailing these results. Investors should note that the company also provided supplemental unaudited financial information (Exhibit 99.2) specifically addressing the impact of the Allergan plc acquisition, which closed on May 8, 2020. This supplemental data includes "as if" comparable key product revenues for periods prior to the actual closing date, allowing for a more continuous view of performance. This filing serves as the primary channel through which AbbVie communicates its quarterly financial performance and the immediate financial implications of significant strategic events like the Allergan acquisition. Investors seeking a comprehensive understanding of AbbVie's Q2 2020 performance and the pro forma financial picture post-Allergan merger should refer to the furnished exhibits for detailed financial tables and commentary.
Key Highlights
- 1AbbVie announced its financial results for the second quarter ended June 30, 2020, via a press release filed with the 8-K.
- 2The report includes a press release detailing Q2 2020 financial results (Exhibit 99.1).
- 3Supplemental unaudited financial information related to the Allergan plc acquisition is provided (Exhibit 99.2).
- 4The Allergan acquisition closed on May 8, 2020.
- 5Exhibit 99.2 offers 'as if' comparable key product revenues for historical periods, assuming the Allergan acquisition closed on January 1, 2019.
- 6This allows investors to analyze product revenue trends more consistently, incorporating the impact of Allergan prior to the actual closing date.
- 7The filing also includes standard XBRL exhibits for regulatory compliance.